{
    "patient": {
        "Name": "Jason Summers",
        "DateOfBirth": "1995-02-28",
        "Sex": "Female",
        "Diagnosis": "Invasive ductal carcinoma",
        "BodyPart": "Breast",
        "Physician": "Dr. Patricia Burgess MD",
        "TreatingInstitution": "Henry LLC"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Breast",
            "CollectedDate": "2023-11-28",
            "ReceivedDate": "2023-11-28",
            "TumorPercentage": "10%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-11-30",
            "ReceivedDate": "2023-11-30"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "BLM",
                "DNA Alteration": "c.2207_2212delinsTAGATTC",
                "GeneMutation": "p.Y736fs*4 Frameshift-GOF",
                "VariantAlleleFraction": "29.51%"
            },
            {
                "Gene": "PDGFRB",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.T681I Spliceregionvariant-LOF",
                "VariantAlleleFraction": "7.47%"
            },
            {
                "Gene": "CHD6",
                "DNA Alteration": "c.4800C>G",
                "GeneMutation": "p.I1600M Spliceregionvariant-LOF",
                "VariantAlleleFraction": "11.65%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": "p.I1600M Nonsense-LOF",
                "VariantAlleleFraction": "15.67%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "ERCC2",
            "KIT",
            "KLF4",
            "FBXW7"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "46 m/Mb",
            "Tmbpercentile": "53%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Equivocal"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.E504K Nonsense-LOF",
                "VariantAlleleFraction": "24.57%"
            },
            {
                "Gene": "RNF43",
                "DNA Alteration": "c.505G>A",
                "GeneMutation": "p.E318D Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "15.53%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.V49M Stopgain-LOF",
                "VariantAlleleFraction": "2.42%"
            },
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G751A Spliceregionvariant-GOF",
                "VariantAlleleFraction": "4.39%"
            },
            {
                "Gene": "FGFR2",
                "DNA Alteration": "c.755C>G",
                "GeneMutation": "p.C382R Nonsense-LOF",
                "VariantAlleleFraction": "5.58%"
            },
            {
                "Gene": "EGFR",
                "DNA Alteration": "c.2239_2256del18",
                "GeneMutation": "p.L747_P753del Frameshift-LOF",
                "VariantAlleleFraction": "2.96%"
            },
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.E504K Frameshift-LOF",
                "VariantAlleleFraction": "7.78%"
            },
            {
                "Gene": "CDC73",
                "DNA Alteration": "c.1A>G",
                "GeneMutation": "p.M1V Spliceregionvariant-GOF",
                "VariantAlleleFraction": "5.71%"
            },
            {
                "Gene": "IDH2",
                "DNA Alteration": "c.419G>A",
                "GeneMutation": "p.R172K Nonsense-LOF",
                "VariantAlleleFraction": "7.38%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "BRCA1"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "BLM",
                "DNA Alteration": "c.2207_2212delinsTAGATTC",
                "GeneMutation": "p.Y736fs*4 Frameshift-GOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "29.51%"
            },
            {
                "Gene": "PDGFRB",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.T681I Spliceregionvariant-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "7.47%"
            },
            {
                "Gene": "CHD6",
                "DNA Alteration": "c.4800C>G",
                "GeneMutation": "p.I1600M Spliceregionvariant-LOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "11.65%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": "p.I1600M Nonsense-LOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "15.67%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-11-26"
    },
    "other": {
        "ReportId": "4989",
        "ReportDate": "2023-12-06",
        "SignedBy": "Patricia Burgess MD",
        "Supervisor": "Dr. Megan Frey"
    }
}